argenx SE is a biopharmaceutical company dedicated to the discovery development and commercialization of antibody based therapeutics for autoimmune diseases. The company uses its proprietary SIMPLE ANTIBODY platform to generate product candidates that target the neonatal Fc receptor complement components and other immune mediators. Its lead product VYVGART is an FcRn inhibitor approved for the treatment of generalized myasthenia gravis, chronic inflammatory demyelinating…
argenx SE is a biopharmaceutical company dedicated to the discovery development and commercialization of antibody based therapeutics for autoimmune diseases. The company uses its proprietary SIMPLE ANTIBODY platform to generate product candidates that target the neonatal Fc receptor complement components and other immune mediators. Its lead product VYVGART is an FcRn inhibitor approved for the treatment of generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and immune thrombocytopenia in more than thirty countries. Argenx SE aims to treat fifty thousand patients globally by 2030 and continues to advance a broad pipeline that includes efgartigimod, empasiprubart, adimanebart, and several early stage programs.
argenx SE generates revenue primarily from product sales of VYVGART in its intravenous, subcutaneous, and prefilled syringe formulations which together accounted for $4.2 billion in net sales during 2025. In addition the company receives royalty income and milestone payments from licensing agreements such as the collaboration with Zai Lab for Greater China and the partnership with AbbVie for the antibody drug conjugate targeting GARP. The firm also earns revenue from outlicensed candidates such as cusatuzumab and receives manufacturing support from partners including Lonza and Fujifilm which contribute to its supply chain.
Within the biotechnology industry argenx SE holds a distinctive position as a pioneer in FcRn based therapeutics with VYVGART being the first approved product of this class. The company competes with other biopharma firms developing FcRn inhibitors, complement C2 inhibitors, and novel immunomodulators but differentiates itself through its proprietary SIMPLE ANTIBODY platform and related engineering technologies that enable rapid identification of novel targets. Its strong intellectual property portfolio which includes hundreds of patent applications and granted patents provides a barrier to entry while its diversified pipeline of late stage and early stage candidates supports sustained growth. Furthermore argenx SE benefits from a scalable manufacturing network that partners with established contract manufacturers to meet global demand. The firm’s commitment to scientific innovation and robust intellectual property protection further strengthens its standing in the market.
The company serves hospitals, clinics, and specialty care centers in the United States, Europe, Japan, and Canada that administer its therapies to patients suffering from autoimmune conditions such as generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and immune thrombocytopenia. It also collaborates with pharmaceutical partners including Zai Lab and AbbVie which act as joint development and commercialization allies in specific geographic regions. As of 2025 VYVGART had been administered to more than 19,000 patients across three indications and three product presentations.